The mechanisms leading to an expanded neutrophil and monocyte supply after stroke are incompletely understood.
T he majority of strokes result from thrombotic events leading to ischemic injury of the brain. This sterile injury to the brain triggers a profound reaction of the immune system. Microglia, which are the most numerous resident immune cells of the central nervous system, proliferate and undergo inflammatory activation. Importantly, brain ischemia also triggers a systemic immune response. Although blood lymphocyte numbers decline, levels of circulating neutrophils and monocytes increase in stroke patients. 1, 2 These myeloid cells are recruited to the brain 3 where they may contribute to the brain's recovery but also to reperfusion injury. Thus, the systemic number of innate immune cells, which recent studies relate to outcomes in patients, 2, 4, 5 increases acutely after stroke. These increased levels of circulating cells may reflect demargination from tissue vascular beds or increased production.
Here we tested whether increased cell production contributed to this observed phenomenon. Innate immune cells have a life span on the order of hours to a few days. The number of leukocytes in blood is limited, and cell reserves in the marginal blood pool, the bone marrow, and the spleen exhaust rapidly after ischemic injury. We therefore examined the source of increased innate immune cell numbers in the circulation and in the ischemic brain and the signals that regulate leukocyte supply after stroke. We hypothesized that bone marrow hematopoietic stem cells (HSC), a source of neutrophils and monocytes in the steady state, increase activity after transient middle cerebral artery occlusion (tMCAO) in mice. January 30, 2015 We report that tMCAO activates the hematopoietic system at its most upstream point. Shortly after brain injury, HSC enter the cell cycle, giving rise to downstream myeloid progenitors and innate immune cells. Bone marrow hematopoiesis acquires a strong myeloid bias, with reduced frequency of lymphoid progenitor cells. Increased autonomic nervous system activity after stroke activates HSC through modulation of the hematopoietic bone marrow niche environment, contributing to the leukocytosis observed in patients.
Methods
A detailed method section is available in the Online Data Supplement.
Animals and Stroke Procedure
Adult C57BL/6 and FVB/N mice (10-12 weeks old) were obtained from Jackson Laboratories, and repTOP TM mitoIRE mice were purchased from Charles River Laboratories. Adrb3 −/− mice (gift from P. Frenette) and Nestin-GFP (green fluorescent protein) reporter mice (gift from G. Enikolopov) were bred in our facilities. Experimental stroke was induced by a tMCAO. The Subcommittee on Research Animal Care at Massachusetts General Hospital approved all procedures.
In Vivo Staining of Bone Marrow Vasculature and Bone Lining Cells
To visualize bone structures, mice were administered intravenously with OsteoSense® 750EX (4 nmol/mouse, PerkinElmer). For in vivo endothelial cell labeling, mice were given IV APC antimouse CD31 (MEC13.3), Alexa Fluor® 647 antimouse VE-Cadherin (BV13), and APC antimouse Sca-1 (D7, 2 μg/mouse in 100 μL PBS).
Whole Mount Immunofluorescence Staining of the Sternum
Sterna were harvested and processed as described previously, 6 sectioned longitudinally, and stained with rabbit antimouse tyrosine hydroxylase antibody (Millipore). Samples were incubated with secondary antibody and imaged using an Olympus IV100 microscope.
Confocal Microscopy
For serial intravital microscopy of the calvarium, signaling lymphocytic activation molecule (SLAM) HSCs were FACS (fluorescence-activated cell sorting)-sorted, labeled with DiD (1,1′-dioctadecyl-3,3,3′,3′-tetramethylindodicarbocyanine perchlorate, Molecular Probes) and injected intravenously into nonirradiated Nestin-GFP recipient mice. The GFP signal, although not specific for mesenchymal stem cells, guided revisiting similar regions of interest in serial intravital imaging. To highlight bone architecture, OsteoSense 750EX was administered (PerkinElmer). We used rhodamine-labeled Griffonia simplicifolia lectin (RL-1102, Vector Laboratories) to outline the vasculature. In vivo imaging was performed on days 1 and 5 after the adoptive cell transfer with a confocal microscope (IV100 Olympus). Z-stacks images for each location were acquired at 2 μm steps. For visualization of Lin − c-Kit + Sca-1 + (LKS) cells in sternum, Lin − c-Kit + Sca-1 + cells were FACS-sorted and labeled ex-vivo with 2 different fluorescent dyes, including CellTracker TM CM-Dil and SP-DiOC18(3) (Molecular Probes) before adoptive transfer into recipient mice.
Results

Bone Marrow Activity Increases After Stroke
We used a tMCAO in mice to address the link between the bone marrow and blood monocytosis and neutrophilia seen after ischemic brain injury in patients 7, 8 and rodents. [9] [10] [11] [12] Because mature myeloid cells, which are recruited to the inflamed brain and contribute to stroke, originate in the bone marrow, we evaluated bone marrow myeloid cell subsets by flow cytometry following stroke induction. Although infarct sizes were comparable on day 1 and day 3 after tMCAO ( Figure 1A) , the percentages and numbers of mature CD11b + cells (Online Figure I ; Figure 1B ), including neutrophils ( Figure 1C ) and inflammatory Ly6C high monocytes ( Figure 1D ), significantly increased in the bone marrow when compared with naive control mice. In contrast, bone marrow Ly6C low monocyte levels did not change. Bone marrow myeloid cell content increased somewhat, but remained significantly lower after a sham procedure that exposed mice to similar surgical trauma as tM-CAO but did not induce brain ischemia (Online Figure IIA) .
To investigate whether the bone marrow undergoes broad activation after experimental stroke, we took advantage of MITO-Luc (mitosis-luciferase) mice. 13 These transgenic mice harbor a transgene in which luciferase gene expression is driven by the activity of a Nuclear Factor-Y-dependent cyclin B2 promoter. This enabled us to noninvasively monitor cell proliferation in the bone marrow of living mice before and after ischemic brain injury over a 2-week period. As shown in Figure 1E , bone marrow luciferase activity increased rapidly after stroke, peaked on day 4, and returned to baseline levels by day 14. Sham surgery did not lead to a significant increase of bone marrow bioluminescence on day 4 (Online Figure IIB ).
Stroke Accelerates Myelopoiesis
After stroke, myeloid cells, especially neutrophils and monocytes, increase their presence in circulation. These cells are also recruited to the ischemic brain. Encouraged by the observed increase of proliferation imaging signal, we therefore next focused on hematopoiesis' contribution to increased systemic leukocyte numbers. Whole bone marrow cultures from animals with stroke gave rise to higher numbers of colonies after 7 days ( Figure 1F ), reflecting increased hematopoietic progenitor cell activity. To further explore the marrow's response following tMCAO, we performed flow cytometry to examine whether the increased mature myeloid cell numbers arise from upstream myeloid progenitor's activity. We observed a significant increase in both, relative frequencies and absolute numbers of Lin − c-Kit + Sca-1 − CD16/32 + CD34 + granulocyte macrophage progenitors and Lin − c-Kit + Sca-1 − CD16/32 + CD34 + CD115 + macrophage and dendritic cell progenitors after tMCAO ( Figure 1G ). After sham surgery, a mild increase of granulocyte macrophage progenitors and macrophage and dendritic cell progenitors did not reach statistical significance when compared with naive controls. Their numbers remained significantly lower than what was observed after tMCAO (Online Figure IIC and IID).
To determine whether myeloid progenitors increased proliferative activity in the context of stroke, mice were given IP injections of 5-bromo-2-deoxyuridine (BrdU) on day Figure 1H ). To decipher whether downstream mature neutrophils and monocytes derive from the accelerated proliferation of myeloid progenitors, we next examined BrdU incorporation into these differentiated cells. Indeed, higher numbers of both neutrophils and monocytes ( Figure 1I ) had incorporated BrdU ( Figure 1J ) after stroke, indicating that they had recently emerged from cycling progenitors. Because each granulocyte macrophage progenitors or macrophage and dendritic cell progenitors can give rise to multiple neutrophils and monocytes, the increase in BrdU + cells was more pronounced in differentiated leukocytes than in progenitors.
Stroke Induces a Myeloid Bias of Hematopoiesis
Leukocytosis after stroke is often associated with lymphopenia. We therefore also examined behavior of lymphoid committed progenitors in the bone marrow after stroke. In contrast to the expansion of myeloid progenitor cells, flow cytometric analyses of lymphoid progenitors revealed a drastic reduction in both the relative frequency and absolute number of Lin − IL7Rα + c-Kit int Sca-1 int common lymphoid progenitors, starting as early as day 1 after stroke induction ( Figure 2A ). Early immature B cells defined as Lin − B220 int CD93 + were significantly diminished in the bone marrow on day 3 after tMCAO ( Figure 2B ). Altogether, the divergent activity changes of myeloid and lymphoid progenitors suggest that stroke may skew hematopoiesis toward the myeloid lineage.
To further explore this hypothesis, we FACS-sorted LKS from mice 3 days after tMCAO. These cells occupy a position in the hematopoietic tree that is just upstream of the divergence of lymphopoiesis and myelopoiesis. Consistent with the activation and expansion of myeloid progenitors at the expense of lymphoid progenitors, LKS from mice with stroke expressed higher levels of NF-κB as well as transcription factors involved in myeloid differentiation, such as PU.1 and CEBPβ. 14, 15 Furthermore, expression of several myeloidspecific genes, including S100A9 and S100A8 alarmins, myeloperoxidase, and chitinase 3-like-3, were also increased in LKS isolated from animals with stroke ( Figure 3 ). In contrast, expression levels of mtg16, Mcsfr, c-myb, and irf8 were not altered (Online Figure III) . In agreement with the severe reduction of lymphoid progenitors and despite unchanged Ikaros expression levels, IL7Rα, which is expressed by lymphoid LKS, was significantly reduced after tMCAO, highlighting a blockade of lymphoid commitment ( Figure 3 ).
HSC Are the Upstream Point of Bone Marrow Activation After Stroke
Because myeloid but not lymphoid progenitors increased activity after stroke, we next asked whether upstream hematopoietic stem and progenitor cells, which give rise to these cells, also respond to ischemic brain injury. Both relative percentages and absolute numbers of LKS in the femur bone marrow were significantly elevated after stroke ( Figure 4A ). The frequency and absolute number of the most upstream SLAM HSC subpopulation (Lin − c-Kit + Sca-1 + CD48 − CD150 + ) increased in mice with tMCAO ( Figure 4A ; see Online Figure  IV for expanded gating strategy). Notably, the extent of the bone marrow HSC response correlated with infarct size ( Figure 4B ). Sham surgery did not result in significantly increased stem cell numbers (Online Figure IIE and IIF) . The increase in numbers of HSC after stroke was corroborated by higher percentages of both LKS and SLAM HSCs in the non G0 phase of the cell cycle 24 hours after stroke, as assessed by flow cytometry after ki-67 staining ( Figure 4C ). These data indicate that HSC enter the cell cycle, expand in numbers, and give rise to downstream progeny after ischemic stroke.
To directly visualize the proliferation of upstream stem and progenitor cells in the bone marrow after stroke, we performed ex vivo confocal microscopy on sternal bone marrow preparations after adoptive transfer of labeled LKS. One day before tMCAO, nonirradiated recipients received an intravenous mixture of FACS-sorted LKS that were labeled with 2 differently colored fluorescent membrane dyes (40 000 LKS per mouse; 1:1 cell ratio). Three days after stroke and 4 days after adoptive cell transfer, red CM-Dil + and green SP-DiOC18(3) + LKS were imaged in the sternal bone marrow, using naive control recipients without stroke as controls. The number of cell clusters, that is, >2 cells in direct proximity, was increased in the marrow of mice with stroke ( Figure 5 ). Notably, we never observed clusters containing a mix of red and green cells, indicating that proximate LKS likely proliferated after seeding the marrow.
We next performed serial intravital microscopy of the skull bone marrow after intravenous adoptive transfer of 20 000 FACS-sorted DiD-labeled SLAM HSCs, cells that are upstream of LKS, into Nestin-GFP recipient mice. The GFP signal, together with vascular dye, aided in relocation of the same bone marrow regions in the second imaging session. Calvaria were imaged 1 day before and again 3 days after stroke, enabling us to serially monitor individual HSCs. Similar to transplanted LKS, SLAM HSCs also increased in number 3 days after tMCAO ( Figure 6 ). Collectively, these data indicate that ischemic injury of the brain triggers proliferation of the most upstream hematopoietic stem and progenitor cells, Figure 6 . Serial intravital microscopy reports increased hematopoietic stem cells (HSC) expansion in the bone marrow of mice with stroke. Mice with and without stroke were transplanted with 20 000 FACS (fluorescence-activated cell sorting)-sorted donor Lin − c-kit + Sca-1 + CD48 − CD150 + HSC labeled ex-vivo with DiD (1,1′-dioctadecyl-3,3,3′,3′-tetramethylindodicarbocyanine perchlorate) fluorescent dye. Intravital microscopy of the mouse calvarium was performed serially, 1 day before and again 3 days after transient middle cerebral artery occlusion (tMCAO). Blue color represents the fluorescence signal produced by the bone imaging agent Osteosense-750; the fluorescence lectin signal stained blood vessels in red. DiD labeled HSC are shown in white. Scale bar represents 50 μm. Bar graph displays the fold increase of HSC per field of view between the 2 imaging sessions in both groups (n=3 mice per group). Mean±SEM, *P<0.05. suggesting that the entire hematopoietic tree, but especially the myeloid lineage, increases proliferation and causes the blood leukocytosis observed in patients after stroke.
Stroke Increases the Sympathetic Tone in Bone Marrow
HSC activity is regulated by the microenvironment of the bone marrow stem cell niche. Interestingly, autonomic tone, which is increased after stroke, [16] [17] [18] [19] may influence the signaling of hematopoietic niche cells. 20, 21 Local sympathetic nerve fibers may release norepinephrine within the bone marrow to increase cell cycling, as observed in circadian rhythms or after MI 20, 21 and in mice exposed to chronic psychosocial stress. 22 We therefore studied whether sympathetic tone alerts bone marrow cells after stroke.
Norepinephrine content in the bone marrow of mice with tMCAO increased significantly ( Figure 7A ). In line with this finding, immunofluorescence staining for tyrosine hydroxylase, the rate limiting enzyme in norepinephrine synthesis, was more pronounced in whole mount sternal preparations 1 day after cerebral ischemic injury. The increased staining pattern followed the typical distribution of sympathetic nerve fibers along bone marrow arterioles ( Figure 7B and 7C) . Norepinephrine indirectly regulates hematopoietic stem and progenitor cells migration and proliferation by modulating stromal cell expression of several factors, including Cxcl12, 20 which retains HSC in position and promotes a quiescent HSC state. In whole bone marrow, Cxcl12, VCAM-1, stem cell factor, angiopoietin-1, and IL-7 mRNA fell significantly 24 hours after tMCAO ( Figure 7D ), indicating that after stroke, the molecular interaction between stromal niche cells and hematopoietic cells is markedly altered.
Bone Marrow β3-Adrenergic Receptor Signaling Activates HSC but not LKS After Stroke
Bone marrow norepinephrine acts through β3-adrenergic receptors expressed by mesenchymal stromal cells, triggering downregulation of above maintenance factors. 20 We attempted to measure expression of the β3-adrenergic receptor in HSC and LKS isolated by flow sorting; however, in contrast to robust expression of this receptor by niche cells, 22 β3-adrenergic receptor mRNA was not detectable in hematopoietic stem and progenitor cells. To determine the role of β3-adrenergic signaling in bone marrow niche cells after stroke, we conducted flow cytometric cell cycle analyses in Adrb3 −/− mice after tMCAO. Because HSC activation correlates with stroke size ( Figure 4B ), only mice with large stroke volumes (defined as >35 mm 3 ) were used for this analysis (wild-type, 71.2±21.2; Adrb3 −/− , 68.5±10.3 mm 3 ). In wild-type mice, LKS and HSC increased frequencies in both G1 and S/G2/M cell cycle phases 1 day after tMCAO ( Figure 8A and 8B) . In contrast to wild-type mice, in which the number of cycling HSC rose to 7.32%±0.52% after tMCAO, HSC in mice with genetic deficiency for the β 3 adrenergic receptor did not increase cycling (3.74%±0.33%, P<0.01 versus wild-type tMCAO), suggesting that the sympathetic nervous system regulates HSC activation through this receptor. Downstream LKS increased cell cycle entry after stroke in Adrb3 −/− mice ( Figure 8C and 8D) . Twenty-four hours after tMCAO, infarct size was comparable in Adrb3 −/− and FVB/N wild-type control mice (48.0±8.8 versus 42.9±14.6; P=0. 23, n=8-14) . The loss of body weight after stroke was comparable in both cohorts (Adrb3 −/− 2.6±0.2 g, FVB/N 2.6±1.1 g; P=0.49).
Altogether, these data are consistent with the notion that after ischemic stroke, sympathetic nervous signaling acts on hematopoietic niche cells, which then alter the bone marrow microenvironment to push increased numbers of HSC into the cell cycle.
Discussion
In contrast to a maturing knowledge on local inflammation in the brain and changes in circulating immune cells, 9, 11, 12, 23 remarkably little is known about how the bone marrow, the primary site of hematopoiesis, reacts to ischemic stroke. 24, 25 In the present study, we report that tMCAO in mice activates HSC and downstream hematopoietic progenitors, leading to an increased output of inflammatory monocytes and neutrophils, whereas the number of lymphocyte progenitors declined. We identify enhanced bone marrow adrenergic signaling through the β3 adrenoreceptor on niche cells as a mechanism of HSC activation. As a result, niche cells altered expression of cytokines and retention factors that regulate hematopoiesis.
Cells residing in the hematopoietic niche regulate leukocyte production through several soluble signals and adhesion molecules. These cells include mesenchymal stem cells, perivascular cells, endothelial cells, macrophages, and osteoblasts. 26, 27 Integration of cell-cell communication informs HSC whether they should remain quiescent, proliferate, differentiate, or migrate. Quiescent HSC and cycling downstream progenitors may reside in different bone marrow locations. 28 Some reports indicate that the most upstream, quiescent HSC reside close to the endosteum next to arterioles ensheathed with nestin-expressing mesenchymal stem cells, whereas more downstream precursors may locate in proximity to sinusoids. 29 Several key niche components, including Cxcl12 (also known as SDF-1), are provided by multiple cell types altering the localization and quiescence of HSC. 30 During circadian oscillation of bone marrow activity, 20 after myocardial infarction, 21 and in mice exposed to chronic psychosocial stress, 22 the sympathetic nervous tone changes, reflected by increased bone marrow levels of norepinephrine. This neurotransmitter binds β3 receptors on niche cells, which leads to downregulation of maintenance factors in the niche. 20 Reduction of the quiescence signal Cxcl12 increases HSC activity, 26, 27 in parallel to what we observed in mice with stroke. Thus, it seems that several stimuli, including circadian rhythms, ischemic injury, and chronic psychosocial stress, converge on a similar neuro-immunologic pathway.
Cxcl12 and IL7, whose expression fell after stroke, are also essential for the development of lymphoid progenitors, such as early B cell precursors and common lymphoid progenitors. 31, 32 As stem cells, lymphoid, and myeloid precursors in the bone marrow may not share the same microenvironmental niches for their respective maintenance and development, it is likely that stroke has broad but differential effects on multiple hematopoietic niches.
Genetic deficiency of β3 adrenoreceptor abolished the increase in HSC cycling after tMCAO; however, downstream LKS were still activated in Adrb3 −/− mice. This interesting divergence suggests that specific regulation of progenitor cell classes may occur, possibly via differences in their location. Increased sympathetic signaling may primarily affect mesenchymal cells that are located next to arterioles in quiescent niches 29 and therefore reach HSC residing there. After activated HSC translocate to positions closer to sinusoids, they may be exposed to different, potentially soluble signals, for example, circulating danger-associated molecular patterns. 33 For instance, hematopoiesis increases in response to toll-like receptor ligands 34 or interferons 35, 36 in the setting of infection. In the context of stroke, break down of the blood-brain barrier allows systemic distribution of circulating messengers, including inflammatory cytokines and alarmins liberated from ischemic and necrotic brain cells, which could likewise alert the hematopoietic system. [37] [38] [39] [40] How local or circulating stimuli, including danger signals, chemokines, survival factors, and proinflammatory cytokines may differentially affect distinct progenitor cell subsets (ie, myeloid versus lymphoid) or their respective niches in the bone marrow after stroke will be the focus of future studies. Experiments with cell-specific deletion of the β3-adrenergic receptor should further refine the cellular identity of involved niche cells.
Although activation and proliferation of microglia dominate the early cellular response to stroke, break down of the bloodbrain barrier also enables robust recruitment of circulating immune cells, including neutrophils and monocytes. 3, 23, 41, 42 These cells are centrally involved in wound healing, including the healing of ischemic wounds. After myocardial infarction, monocytes are essential for tissue repair, but their oversupply is detrimental for healing and leads to heart failure. 43 Macrophage depletion studies suggest comparable mechanisms for brain ischemia because lack of these cells leads to hemorrhagic conversion of ischemic stroke. 44 On the other end of the spectrum, the level of inflammatory monocyte subtypes in blood correlates with worse outcome in stroke patients. 2 Thus, there may be a hypothetical sweet spot of immune cell activity after stroke, in which salutary functions of resident microglia and recruited myeloid cells support resolution of inflammation and regeneration of the injured brain.
Thirty percent of acute stroke patients acquire infections, especially pneumonia. 45 Although infections frequently occur after any injury, and stroke-related sequela such as paralysis may also contribute, the high incidence of poststroke infections is accompanied by lymphocyte apoptosis. Some authors postulated the existence of a peripheral immunosuppression, reporting an impressive atrophy of the thymus and the spleen after stroke that lasted for several days thereafter, a phenotype attributed to lymphocyte apoptosis. 9, 16 Our data indicate that hematopoiesis increased and that the bone marrow accelerated production of innate immune cells, pointing to an important exception from the peripheral immunosuppression after stroke. The lymphoid lineage suppression we observed in the bone marrow of mice with stroke may contribute to the previously reported blood lymphopenia. 9, 16 The leukocytes that are supplied to the ischemic brain and circulate in increasing numbers after stroke are also a driving force behind complications of atherosclerosis. Monocytes give rise to plaque macrophages and foam cells, which become apoptotic and form necrotic cores. Macrophage-derived proteases digest the protective fibrous cap. 43 Such a destabilized plaque (eg, within the carotid artery) may rupture and lead to ischemia of the brain. We recently described that experimental myocardial infarction accelerates hematopoiesis and atherosclerosis, 21 possibly explaining the high secondary event rates observed in patients with a first infarct. Likewise, stroke may increase the supply of neutrophils and monocytes to remote atherosclerotic plaque, thus promoting stroke reoccurrence.
In ischemic heart disease, blood leukocytosis is associated with worse outcome. There are limited data for stroke patients, possibly reflecting that leukocytes and their subsets have dual roles, including support of recovery and healing. In addition, stroke pathophysiology is heterogeneous and patients often suffer from infections, which can influence leukocyte levels.
In 1999, the Stockholm study 46 reported that when controlled for initial stroke severity, multivariate regression analysis did not show association of leukocytosis to outcome. This study included patients with hemorrhagic stroke, and CT identified infarction in 60% of the population. A more recent study, which only included patients with ischemic stroke, found an association of leukocytosis with early poor outcome. 5 Another report correlated increased CD14 high CD16 − monocyte levels with worse 90-day outcome and higher mortality in patients after adjustment for age and symptoms on admission. 2 Many preclinical studies imply that anti-inflammatory intervention may improve stroke recovery. 23 However, translation of these studies into clinical therapy has proven difficult, arguing that better understanding of systemic leukocyte subset fate in the setting of stroke is warranted. 33 Our study reports that increased signaling of the sympathetic nervous system activates HSC activity in the bone marrow, increasing the output of neutrophils and inflammatory Ly-6C high monocytes after stroke. At the present time, it is unclear whether the bone marrow's response to stroke represents a therapeutic target to improve stroke recovery and to prevent secondary stroke. Preclinical [47] [48] [49] and some early clinical 50, 51 data suggest that beta blocker use may be beneficial after stroke. Observed effects may or may not be related to bone marrow activity because the affinity of most clinical beta blockers for the β3 adrenoreceptor is low. Beta blockers lower blood pressure, which likely also influences outcome and reoccurrence of stroke. In addition, bone marrow-derived immune cells may support stroke recovery. Hence, although targeting overproduction of inflammatory immune cells is worthwhile in cardiovascular disease, 52 there is a compelling need to gather additional data on precisely when and how to therapeutically intervene after stroke.
